What QSimulate does

QSimulate is a Boston-based quantum simulation software company founded in 2019 by theoretical chemists Toru Shiozaki (CEO) and Garnet Chan (Chief Visionary Advisor). The company builds GPU-accelerated quantum-mechanics simulation tools that apply quantum physics directly to computational drug discovery, most notably through its QUELO platform, which uses quantum-mechanics-based free energy perturbation (FEP) to predict drug-target binding affinities. The product portfolio is anchored by the proprietary GECQO quantum-mechanics engine and extends across specialized modules: QuValent for covalent drug design, QuaiPa for peptide parameterization, QuantumFP for generating quantum-accurate molecular fingerprints at scale, and ProtClean/LigClean for molecular preparation. The QSP Life platform integrates these capabilities into drug-discovery workflows, while QSP Materials extends the same approach to materials science and the QSimulate-QM/GENESIS integration serves academic and government researchers in partnership with RIKEN.

The company sells primarily to pharmaceutical and biotechnology enterprises through a sales-led, direct enterprise motion supplemented by a free QUELO Experience pilot program; named customers include Psivant Therapeutics, Alterome Therapeutics, Architect Therapeutics, Septerna, and JSR Corporation. Revenue mechanics combine cloud-based SaaS access (running on AWS HPC infrastructure including EC2 G6e Instances and NVIDIA L40S GPUs) with usage-based pricing measured per conformer calculation and an annual academic licensing channel. Strategic relationships with Google Quantum AI, NVIDIA, AWS, RIKEN's Sugita Group, and Mitsui-Q underpin both the technology stack and the APAC distribution pathway through QIDO. As of November 2025, QSimulate had raised over $11 million in cumulative seed funding and operated offices in Boston, Berkeley, Ghent, and Tokyo with a headcount in the 11-50 range.

Name

QSimulate

Legal name

Quantum Simulation Technologies, Inc.

Website

https://qsimulate.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

QSimulate builds GPU-accelerated quantum simulation software, anchored by the QUELO platform, for pharmaceutical, biotechnology, and materials science customers applying quantum-mechanics-based free energy perturbation to accelerate drug lead optimization.

Ownership category

akta.pro rank

Product category

Computational Drug Discovery Software

NAICS

Scientific Research and Development Services (5417)

akta.pro primary industry

Quantum Software, Compilers, Verification & Benchmarking Research (HDAGAMAF)

akta.pro secondary industry

Quantum Cloud Infrastructure & QPU Hosting (HDAGAIAA)

Keywords

• Computational drug discovery
• Quantum chemistry simulation
• Molecular modeling software
• Free energy perturbation
• GPU-accelerated science

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Cloud-based SaaS Platform: Subscription-based access to QUELO and other quantum simulation platforms running on cloud HPC resources (AWS). Customers pay for compute usage through the platform, achieving 100-1000x compute cost savings compared to traditional approaches.
2. Usage-based Computing: Platform optimized for 'spot instance' computing allowing customers to calculate vast quantities of quantum mechanical data at significantly reduced costs. Pricing measured per conformer calculation.
3. Academic Licensing: Academic licensing program for QSimulate-QM/GENESIS integration provided to research groups and shared facilities at academic and government institutions. Pricing provided upon inquiry.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

QSimulate provides cloud-delivered, GPU-accelerated quantum mechanics simulation software for pharmaceutical and materials science R&D. Its flagship QUELO platform applies quantum-mechanical Free Energy Perturbation (FEP) directly to drug lead optimization, enabling accurate binding affinity predictions for challenging ligand classes (covalent, halogenated, charged, polarizable, metalloproteins, RNA), supplemented by modules such as QuValent, QuaiPa, QuantumFP, ProtClean, and QSP Materials that together target a 1,000x speedup and 100-1,000x compute cost reduction versus traditional QM methods.

Product overview

QSimulate provides a quantum simulation platform for computational drug discovery, consisting of the core QUELO platform augmented by specialized modules. The portfolio includes QUELO for lead optimization using quantum mechanics-enhanced FEP; QuValent for covalent binder design; QuaiPa for peptide parameterization; QuantumFP for generating quantum mechanical fingerprints as training data for AI models; ProtClean and LigClean for molecular preparation; QSP Life for broader drug discovery workflows; QSP Materials for materials design; and QSimulate-QM/GENESIS for academic molecular dynamics research. The platform operates on GPU architectures (GECQO engine) and runs on AWS HPC resources.

Differentiator

Problem solved

Functional benefit

Brands

• QUELO: Quantum enhanced lead optimization platform for small-molecule, covalent, and peptide drugs
• QuValent
• QuaiPa
• QuantumFP
• ProtClean
• LigClean
• QSP Life
• QSP Materials
• GECQO
• QIDO

Products and services

• QUELO Quantum-enhanced lead optimization platform that applies quantum mechanics directly to free energy perturbation (FEP) experiments for accurate binding affinity predictions. Designed for pharmaceutical and biotech discovery teams, it enables accurate simulation for highly polarizable functional groups, charged ligands, metalloprotein targets, covalent binders, and RNA targets, screening more than 25 ligands per day using quantum mechanics on eight L40S GPUs.
• QuValent Quantum simulation solution specifically designed for warhead tuning in covalent drug design. Covers non-covalent binding, reversible covalent binding, and irreversible covalent binding, and is described as the only computational solution that can evaluate the quantum process of covalent bond formation. Targets medicinal chemists designing covalent inhibitors.
• QuaiPa Quantum-fueled, AI-powered automated peptide parameterization tool that creates QM-defined force fields specifically optimized for peptides of interest in seconds. Built for drug discovery teams working on non-canonical peptides that lack suitable traditional force fields.
• QuantumFP Quantum fingerprinting technology for ML workloads that generates quantum mechanical 3D molecular fingerprints. Achieves throughput of more than 30,000,000 conformers per day with greater than 99.9994% success rate on approximately 1,000,000 molecules, at $15 per 30,000 conformers, supplying quantum-accurate training data for AI drug discovery models.
• ProtClean AI-powered protein preparation tool that automatically cleans and prepares PDB files for computational drug simulations, integrating with the QSP Life workflow for seamless file transfer between tools.
• LigClean Ligand preparation tool with quantum accuracy for computational drug simulations, complementing ProtClean on the structure-preparation side of the QUELO pipeline.
• QSP Life Quantum physics-based drug discovery platform that leverages proprietary quantum algorithms for biological predictions, forming the broader workflow within which QUELO and its preparation modules operate.
• QSP Materials Workflow automation platform for materials design that delivers 1000x throughput improvement through tailored automation of quantum simulation. Used for structure determination, reaction exploration, battery optimization, semiconductor doping, and alloy design by materials science teams.
• QSimulate-QM/GENESIS QM/MM simulation software integrating QSimulate-QM as the quantum mechanics engine for the GENESIS molecular dynamics package developed with the RIKEN Sugita Group. Enables long-time dynamics and large-scale structure optimization using quantum mechanics, delivered as a ready-to-use Singularity image with technical support to academic and government research institutions.

Quantifiable outcome

• 1,000x speedup in molecular simulation runtimes (months to hours)
• +7 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Partnerships

Five partnerships are on record, tiered core and major.

• Google Quantum AIcoreStrategic or Co-development PartnerCollaboration with Google Quantum AI on quantum computing algorithms for chemical and biomolecular problems. QSimulate leverages proprietary quantum algorithms for biological predictions in partnership with Google's quantum computing initiative.
• Amazon Web Services (AWS)coreTechnology or IntegrationQSimulate's platforms including QUELO run on AWS HPC resources utilizing Amazon EC2 G6e Instances. AWS provides the cloud computing infrastructure enabling the 1,000x speedup and cost optimizations that QSimulate delivers to customers.
• NVIDIAmajorTechnology or IntegrationGECQO engine optimized for NVIDIA GPU architectures including L40S GPUs. NVIDIA co-published a blog post highlighting QUELO G and CUDA Graphs demonstrating the technical partnership in GPU optimization for quantum simulation.
• RIKEN (Sugita Group)majorStrategic or Co-development PartnerQSimulate provides QSimulate-QM as an engine for the GENESIS molecular dynamics package developed by the Sugita group at RIKEN. The combined QSimulate-QM/GENESIS program enables long-time dynamics and large-scale structure optimization using quantum mechanics.
• Mitsui & Co.majorStrategic or Co-development PartnerQIDO (Integrated quantum mechanics/quantum computing product for reaction analysis) is available through partnership with Mitsui-Q, enabling broader market access for quantum chemistry solutions in Japan and Asia Pacific.

Scale indicators7 records

Recent moves6 records

Expansion highlights8 records

Direct peers

• OpenEye Scientific (Cadence Design Systems): Computational chemistry software suite (now part of Cadence) for molecular modeling and drug discovery. Competes with QSimulate's QUELO/QuValent in pharma cheminformatics workflows with broader installed base.
• XtalPi: AI+quantum/physics-based drug discovery company combining computational chemistry with robotic labs. Comparable in combining quantum-physics rigor with scalable computation, and a direct competitor for pharma lead-optimization contracts.
• Schrödinger: Public computational chemistry and materials science platform (NYSE: SDGR) offering physics-based molecular simulation including FEP+ for drug discovery. Most direct competitor to QSimulate, with broader portfolio but less focus on quantum-mechanics-grade accuracy on commodity GPU clouds.
• Chemical Computing Group (CCG): Developer of the Molecular Operating Environment (MOE), a long-standing computational chemistry platform used across pharma R&D. Competes for pharma modeling budgets with more established tooling but less GPU-native and QM-FEP focus.

Broad incumbents

• Dotmatics: Enterprise scientific software platform (now part of Siemens) covering biology, chemistry, and lab informatics. Competes indirectly through workflow platforms that integrate third-party modeling tools, including computational chemistry.

Others

• Google Quantum AI: Quantum computing research division at Alphabet advancing quantum hardware and algorithms for chemistry and biology. Listed as a partnership counterpart but also a long-term ecosystem player whose quantum-computing advances could either enable or threaten QSimulate's classical-quantum-mechanics approach.

Emerging players

• Polaris Quantum Biotech: Quantum computing-native drug discovery startup applying quantum algorithms to chemo-informatics and lead optimization. Comparable to QSimulate's quantum-chemistry angle but takes a quantum-hardware-native path rather than classical-GPU simulation.
• Insilico Medicine: AI-driven drug discovery company combining generative chemistry with biology. Competes for pharma lead-optimization dollars and may erode demand for pure QM-based methods if its accuracy approaches QM-FEP levels.
• Relay Therapeutics: Motion-based drug design company leveraging protein motion and computational chemistry for precision oncology. Comparable in computational rigor applied to lead optimization, with a stronger pipeline but narrower platform scope.
• Atomwise: AI-first small-molecule drug discovery company using deep learning on molecular structures. Competes in pharma hit-to-lead optimization and represents the ML-first alternative to QSimulate's QM-first approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCefPnTnV_AsuLtkSyCwaTBg
• LinkedInlinkedin.com/company/qsimulate

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QSimulate